Eric Lefebvre - Mar 30, 2023 Form 4 Insider Report for PLIANT THERAPEUTICS, INC. (PLRX)

Role: Chief Medical Officer
Signature: /s/Mike Ouimette, attorney-in-fact
Stock symbol: PLRX
Transactions as of: Mar 30, 2023
Transactions value $: -$298,228
Form type: 4
Date filed: 4/3/2023, 07:01 PM
Previous filing: Mar 31, 2023
Next filing: Jul 18, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	PLRX	Common Stock	Sale	-$298K	-11.2K	-7.16%	$26.52	146K	Mar 30, 2023	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id	Content
F1	Represents a nondiscretionary sale by the plan established on behalf of the Reporting Person on July 28, 2022 in a manner intended to satisfy the requirements of Rule 10b5-1. The sale price of the Reporting Person's shares represents the weighted average of all shares sold by a broker at prices ranging from $25.88 to $27.235, inclusive, on March 30, 2023 and March 31, 2023 on behalf of a group of employees of the Issuer, including the Reporting Person, to satisfy the payment of withholding tax liability in connection with the vesting of previously granted performance-vested stock units. The Reporting Person undertakes to provide Pliant Therapeutics, Inc., any security holder of Pliant Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold on behalf of the group of employees of the Issuer at each separate price within the range set forth in footnote (1) to this Form 4.

Content

Represents a nondiscretionary sale by the plan established on behalf of the Reporting Person on July 28, 2022 in a manner intended to satisfy the requirements of Rule 10b5-1. The sale price of the Reporting Person's shares represents the weighted average of all shares sold by a broker at prices ranging from $25.88 to $27.235, inclusive, on March 30, 2023 and March 31, 2023 on behalf of a group of employees of the Issuer, including the Reporting Person, to satisfy the payment of withholding tax liability in connection with the vesting of previously granted performance-vested stock units. The Reporting Person undertakes to provide Pliant Therapeutics, Inc., any security holder of Pliant Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold on behalf of the group of employees of the Issuer at each separate price within the range set forth in footnote (1) to this Form 4.